LONDON, June 16, 2026, 11:04 BST
- Genus shares gained late in London trade. The FTSE 250 slipped.
- JNE Partners LLP crossed the 5% voting-rights threshold, a fresh RNS showed.
- Genus is set to report full-year numbers on September 10. Investors will be watching for more on the China JV cash and PRP sign-offs.
Shares of Genus plc traded higher Tuesday, last quoted at 2,194p to 2,197p in delayed action. That’s up about 0.7% to 0.9%. The move beat the FTSE 250, which dipped 0.10% based on Hargreaves Lansdown’s delayed figures. Genus, listed in the UK, provides animal genetics to dairy, beef, and pork producers. HL
Genus shares didn’t react to earnings, since none were out today. Instead, the company posted a holding notice showing that JNE Partners LLP upped its voting stake to 5.002041% from 4.893850%. That crosses a reporting threshold. Such institutional filings are common and usually read as signals on positioning. It doesn’t impact revenue or profit forecasts and doesn’t by itself change the outlook. The movement in the stock seems tied to how the market is pricing Genus after its earlier profit upgrade, its push in China, and the PRRS-resistant pig program. Genus plc
Bullish bets are still built on profit momentum. In February, Genus booked record adjusted operating profit of £55.8 million for H1, a 38% rise from last year. Adjusted profit before tax came in at £55.7 million, up 57%. Management cuts out a few items from adjusted PBT, saying these can hide the core performance. CEO Jorgen Kokke said there was “broad-based growth across PIC” and “continued improvement in ABS profitability.” Genus also launched its Chinese porcine joint venture, which is expected to bring in close to £100 million in fiscal Q4. The company said Canada’s signoff on its PRP gene edit gives it another regulatory win. Genus PLC
Valuation remains an issue for the bear side. Genus trades at 26.63 times earnings on Hargreaves Lansdown. That’s a high price for a company this size, with first-half revenue at £335.6 million—about flat. Execution risks haven’t gone away. PRP still needs more clearances in some key markets before a full rollout. China is still important for porcine, and the ABS bovine business isn’t clear yet as Asian markets stay tough and China continues to block U.S. bovine genetics. HL
Genus (GNS:LSE) shares have room to rise, at least on paper, according to analyst consensus. Investors Chronicle’s LSEG numbers show 11 analysts as of June 11. The median 12-month target sits at 3,200p, with no Sell or Strong Sell ratings: four Buys, four Outperforms, four Holds. Shares last traded near 2,197p. That leaves upside if the business hits its marks. But after today’s move and with earnings coming at a premium, this is a bet for investors who can deal with biotech regulation risk and livestock market swings, not a safehold for defensive buyers. Investors Chronicle
Genus’s full-year numbers land September 10. Investors are looking for proof that the China JV cash came in, details on how deconsolidation of PIC China will change the accounts, and signs of progress on PRP export approvals for Mexico, Japan, and China. What Genus says here will test if the current share price matches up with delivery, or if investors are hoping for more than earnings can support. Genus PLC
